Press Release

Modella AI Emerges from Stealth with Breakthrough Multimodal and Generative AI Copilots for Pathology

June 18, 2024 – Modella AI, Inc., a trailblazer in artificial intelligence and medical imaging, is excited to announce the launch of its groundbreaking multimodal foundation models and generative AI copilots, designed to revolutionize pathology and enhance diagnostic precision in healthcare.

Spinning out from the Mahmood Lab at Harvard Medical School and Mass General Brigham, Modella AI has developed multimodal, and generative AI models that provide unprecedented accuracy, efficiency, and interactive capabilities for medical imaging analysis. These models are initially focused on pathology, a critical area of medicine where timely and precise diagnoses are paramount. This innovation positions Modella AI at the forefront of revolutionizing the multi-billion dollar histology and cytology market.

Revolutionizing Pathology with Multimodal AI

Modella AI's multimodal foundation models utilize vast datasets of pathology images and corresponding clinical data to train AI systems capable of performing a wide range of downstream tasks. From disease detection and diagnosis to prognosis and therapy prediction, these models represent a significant leap forward in computational pathology, offering a low cost and scalable solution to address global unmet medical needs.

"Our multimodal AI models are designed to understand and interpret complex medical data, offering clinicians powerful tools to enhance their diagnostic capabilities," said Dr. Jill Stefanelli, CEO and Co-founder of Modella AI. "By combining visual information from pathology slides with textual clinical data, we can provide a more comprehensive analysis, ultimately improving patient outcomes."

Generative AI Copilots: The Future of Medical Assistance

In addition to its foundation models, Modella AI is introducing generative AI copilots—advanced assistants that support pathologists by automating routine tasks, generating detailed reports, and providing insights based on the latest medical research. Starting with the first AI copilot, PathChat 2, these AI copilots are designed to work alongside medical professionals, augmenting their expertise and freeing up time for more critical decision-making processes.

"Our generative AI copilots are set to transform the workflow of pathology labs," Dr. Faisal Mahmood, Co-founder of Modella AI added. "By automating repetitive tasks and offering intelligent assistance, our AI copilots enable pathologists to focus on the most complex and impactful aspects of their work, thereby increasing operational efficiency and improving overall accuracy while reducing costs for healthcare providers."

Commitment to Innovation and Collaboration

Modella AI is committed to advancing medical technology through continuous innovation and collaboration with leading healthcare institutions. The company is actively partnering with hospitals, academic institutions, and commercial laboratories to ensure that its AI solutions are aligned with clinical needs and are rigorously validated in real-world settings.

"Our mission is to harness the power of AI to assist healthcare professionals and improve patient care," said Dr. Richard Chen, Chief Technology Officer of Modella AI. "We are dedicated to developing AI technologies that are not only cutting-edge but also practical in driving democratization of medical imaging and interpretation."

About Modella AI

Modella AI is a biomedical artificial intelligence company, pioneering multimodal, generative, and agentic AI for diagnostic, prognostic, and therapeutic workflows. Modella AI holds an exclusive license to PathChat and other foundation models developed in the Mahmood Lab at Mass General Brigham.

For more information about Modella AI and its AI solutions, please visit www.modella.ai or send an email to info@modella.ai.